{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:24:46Z","timestamp":1793982286433,"version":"4.8.0"},"reference-count":166,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In recent years, the pathophysiologic framework of autoimmune hemolytic anemias (AIHAs) has evolved considerably, extending beyond the simplistic paradigm of antibody-mediated red blood cell (RBC) destruction, which is now recognized as a downstream consequence of a broader immune dysregulation. AIHA is fundamentally orchestrated by a complex interplay between innate and adaptive immune components, including autoreactive B and T lymphocytes, macrophages, and the reticuloendothelial system. Central to disease pathogenesis are two interrelated mechanisms: clonal B-cell expansion with autoantibody production and complement activation. These immunologic processes support the heterogeneity of AIHA, delineating distinct clinical entities such as warm AIHA, cold agglutinin disease\/syndrome (CAD\/CAS), and atypical variants, each characterized by specific therapeutic susceptibilities. Glucocorticoids remain the standard first-line therapy for warm AIHA; in contrast, CAD\/CAS is increasingly managed with agents targeting B-cell function or complement activation, including rituximab and sutimlimab. However, therapeutic algorithms are rapidly shifting, particularly in the context of treatment-refractory disease. Emerging therapeutics targeting the classical complement pathway include novel anti-C1s monoclonal antibodies such as riliprubart, which exhibits an extended half-life due to enhanced affinity for the neonatal Fc receptor. Parallel strategies aim to disrupt B-cell receptor (BCR) signaling cascades, employing Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, spleen tyrosine kinase (SYK) inhibitors such as fostamatinib and sovleplenib, and phosphoinositide 3-kinase (PI3K) inhibitors such as parsaclisib. Collectively, these advances are reshaping the therapeutic landscape of AIHA toward a precision medicine model guided by mechanistic insights into disease biology. In this review, we delineate the evolving immunopathogenesis of AIHAs and examine emerging therapeutic strategies, integrating their underlying rationale, clinical data, and implications for future treatment paradigms.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1624667","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:08:24Z","timestamp":1753942104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions"],"prefix":"10.3389","volume":"16","author":[{"given":"Alessandro","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Maria","family":"Mereu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercede","family":"Schintu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01323","article-title":"Pro-inflammatory actions of heme and other hemoglobin-derived DAMPs","volume":"11","author":"Bozza","year":"2020","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123859","article-title":"New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1","volume":"9","author":"Barcellini","year":"2020","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2089115","article-title":"Autoimmune hemolytic anemia: causes and consequences","volume":"18","author":"Fattizzo","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1228142","article-title":"Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps","volume":"14","author":"Mulder","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4065\/78.10.1274","article-title":"Anemia in adults: a contemporary approach to diagnosis","volume":"78","author":"Tefferi","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.690","article-title":"Warm antibody autoimmune hemolytic anemia","volume":"2016","author":"Kalfa","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000779","article-title":"Warm autoimmune hemolytic anemia: new insights and hypotheses","volume":"30","author":"Branch","year":"2023","journal-title":"Curr Opin Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000459","article-title":"Murine models of autoimmune hemolytic anemia","volume":"25","author":"Howie","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mah\u00e9vas","year":"2015","journal-title":"J Autoimmun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015008","article-title":"Red pulp macrophages in the human spleen are a distinct cell population with a unique expression of Fc-\u03b3 receptors","volume":"2","author":"Nagelkerke","year":"2018","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.655393","article-title":"How do red blood cells die","volume":"12","author":"Thiagarajan","year":"2021","journal-title":"Front Physiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01958","article-title":"Expression, role, and regulation of neutrophil fc\u03b3 Receptors","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406192121","article-title":"Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding","volume":"121","author":"Frischauf","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/hemato3040040","article-title":"Cold agglutinin disease: improved understanding of pathogenesis helps define targets for therapy","volume":"3","author":"Berentsen","year":"2022","journal-title":"Hemato"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1002\/9781118493595.ch25","article-title":"I and i Antigens, and Cold Agglutination","volume-title":"Human blood groups","author":"Daniels","year":"2013"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.128538","article-title":"Complement inhibitors to treat IgM-mediated autoimmune hemolysis","volume":"100","author":"Wouters","year":"2015","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009516","article-title":"Clinical and epidemiological features of paroxysmal cold hemoglobinuria: a systematic review","volume":"7","author":"Jacobs","year":"2023","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000897","article-title":"Paroxysmal cold hemoglobinuria successfully treated with complement inhibition","volume":"3","author":"Lau-Braunhut","year":"2019","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27190","article-title":"How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria","volume":"99","author":"Jacobs","year":"2024","journal-title":"Am J Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25212","article-title":"Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers","volume":"93","author":"Barcellini","year":"2018","journal-title":"Am J Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000476","article-title":"Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease","volume":"3","author":"Bylsma","year":"2019","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15757","article-title":"Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia","volume":"20","author":"Fattizzo","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.1182\/blood-2024-212067","article-title":"Risk of venous thromboembolism in hospitalized patients with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia","volume":"144","author":"Eltaher","year":"2024","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021166","article-title":"Rethinking coagulation: from enzymatic cascade and cell-based reactions to a convergent model involving innate immune activation","volume":"142","author":"Yong","year":"2023","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.123.318780","article-title":"Basic mechanisms of hemolysis-associated thrombo-inflammation and immune dysregulation","volume":"43","author":"Dimitrov","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010817","article-title":"Complement and platelets: prothrombotic cell activation requires membrane attack complex-induced release of danger signals","volume":"7","author":"Mannes","year":"2023","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26108","article-title":"Circulating extracellular vesicles and cytokines in congenital and acquired hemolytic anemias","volume":"96","author":"Barcellini","year":"2021","journal-title":"Am J Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.918775","article-title":"Coagulation and complement: Key innate defense participants in a seamless web","volume":"13","author":"Pryzdial","year":"2022","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03334.x","article-title":"Abnormal platelet function in C3-deficient mice","volume":"7","author":"Gushiken","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V68.4.875.875","article-title":"Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase","volume":"68","author":"Wiedmer","year":"1986","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201902397R","article-title":"In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells","volume":"34","author":"Shivshankar","year":"2020","journal-title":"FASEB J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12979-020-00208-7","article-title":"Autoimmune hemolytic anemia: current knowledge and perspectives","volume":"17","author":"Michalak","year":"2020","journal-title":"Immun Ageing"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9403","DOI":"10.1038\/s41467-024-53658-8","article-title":"Molecular mimicry as a mechanism of viral immune evasion and autoimmunity","volume":"15","author":"Maguire","year":"2024","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1881225","article-title":"Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases","volume":"26","author":"Taherifard","year":"2021","journal-title":"Hematology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16883","article-title":"Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19","volume":"190","author":"Angileri","year":"2020","journal-title":"Br J Haematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41594-022-00779-7","article-title":"Structure, dynamics and assembly of the ankyrin complex on human red blood cell membrane","volume":"29","author":"Xia","year":"2022","journal-title":"Nat Struct Mol Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-013-0407-3","article-title":"Complexities in the relationship between infection and autoimmunity","volume":"14","author":"Root-Bernstein","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2010.06.004","article-title":"Immune hemolytic anemia associated with drug therapy","volume":"24","author":"Garratty","year":"2010","journal-title":"Blood Rev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009801","article-title":"Drug-induced immune hemolytic anemia: detection of new signals and risk assessment in a nationwide cohort study","volume":"8","author":"Maquet","year":"2024","journal-title":"Blood Adv"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2011-130364","article-title":"A B cell explanation for autoimmune disease: the forbidden clone returns","volume":"88","author":"McQueen","year":"2012","journal-title":"Postgrad Med J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70327","article-title":"Autoimmune diseases and risk of non-hodgkin lymphoma: A mendelian randomisation study","volume":"13","author":"Shi","year":"2024","journal-title":"Cancer Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225804","article-title":"Autoimmune hemolytic anemia in chronic lymphocytic leukemia: A comprehensive review","volume":"13","author":"Autore","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6216.760","article-title":"Human leucocyte antigens A, B, C, and DRW in idiopathic \"warm\" autoimmune haemolytic anaemia","volume":"280","author":"Abdel-Khalik","year":"1980","journal-title":"Br Med J"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V78.9.2372.2372","article-title":"ariable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens","volume":"78","author":"Silberstein","year":"1991","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116902","article-title":"Naturally occurring anti-i\/I cold agglutinins may be encoded by different VH3 genes as well as the VH4","volume":"92","author":"Jefferies","year":"1993","journal-title":"21 Gene segment J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146126","article-title":"Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity","volume":"101","author":"Ma\u0142ecka","year":"2016","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1182\/blood-2023-174862","article-title":"Exploration of B and T cell receptor repertoires reveals distinct mechanisms in pure red cell aplasia, autoimmune hemolytic anemia, and aplastic anemia","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/cei\/uxad135","article-title":"Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease","volume":"216","author":"Ma\u0142ecka","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2012.01400.x","article-title":"Analysis of polymorphisms of TNF-\u03b1, LT-\u03b1, IL-10, IL-12 and CTLA-4 in patients with warm autoimmune haemolytic anaemia","volume":"34","author":"D'Abronzo","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10278","article-title":"CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders","volume":"72","author":"Pavkovic","year":"2003","journal-title":"Am J Hematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15063","article-title":"Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease","volume":"183","author":"Ma\u0142ecka","year":"2018","journal-title":"Br J Haematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-133760","article-title":"The mutational landscape of cold agglutinin disease","volume":"136","author":"Ma\u0142ecka","year":"2020","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00144-3","article-title":"Diagnosis and management of Evans syndrome in adults: first consensus recommendations","volume":"11","author":"Fattizzo","year":"2024","journal-title":"Lancet Haematol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-11-887141","article-title":"Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes","volume":"134","author":"Hadjadj","year":"2019","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1221582","article-title":"Cytokine polymorphisms in patients with autoimmune hemolytic anemia","volume":"14","author":"Zaninoni","year":"2023","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12624","article-title":"Tumor necrosis factor gene polymorphisms in adult patients with autoimmune hemolytic anemia","volume":"39","author":"Pavkovic","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232337","article-title":"Haploinsufficiency in PTPN2 leads to early-onset systemic autoimmunity from Evans syndrome to lupus","volume":"221","author":"Jeanpierre","year":"2024","journal-title":"J Exp Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1339714","article-title":"Immune tolerance and the prevention of autoimmune diseases essentially depend on thymic tissue homeostasis","volume":"15","author":"Shirafkan","year":"2024","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00970-x","article-title":"Therapeutic induction of antigen-specific immune tolerance","volume":"24","author":"Kenison","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)00080-7","article-title":"Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion","volume":"13","author":"Bouneaud","year":"2000","journal-title":"Immunity"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00350","article-title":"Mechanisms of tolerance induction by dendritic cells in vivo","volume":"9","author":"Hasegawa","year":"2018","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102489","article-title":"Tolerization of recent thymic emigrants is required to prevent RBC-specific autoimmunity","volume":"114","author":"Wong","year":"2020","journal-title":"J Autoimmun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1996.d01-731.x","article-title":"T-helper 1 dominated responses to erythrocyte Band 3 in NZB mice","volume":"89","author":"Shen","year":"1996","journal-title":"Immunology"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02663.x","article-title":"IL-4 and IL-10 modulate autoimmune haemolytic anaemia in NZB mice","volume":"139","author":"Youssef","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/08916930290005891","article-title":"Th1 and Th2 cytokine modulation by IL-10\/IL-12 imbalance in autoimmune haemolytic anaemia (AIHA)","volume":"35","author":"Fagiolo","year":"2002","journal-title":"Autoimmunity"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1383","article-title":"Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen","volume":"100","author":"Hall","year":"2002","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.50","article-title":"The dichotomous nature of T helper 17 cells","volume":"17","author":"Stockinger","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.exphem.2012.08.008","article-title":"Critical role of Th17 cells in development of autoimmune hemolytic anemia","volume":"40","author":"Xu","year":"2012","journal-title":"Exp Hematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4692","article-title":"CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia","volume":"105","author":"Mqadmi","year":"2005","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282859","article-title":"Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor \u03b1 in autoimmune hemolytic anemia and participate in Th17 polarization","volume":"109","author":"Ciudad","year":"2024","journal-title":"Haematologica"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024230","article-title":"Mitigation of checkpoint inhibitor-induced autoimmune hemolytic anemia through modulation of purinergic signaling","volume":"144","author":"Dei Zotti","year":"2024","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1178792","article-title":"T follicular helper cells and T follicular regulatory cells in autoimmune diseases","volume":"14","author":"Qi","year":"2023","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"19767","DOI":"10.1038\/s41598-019-56365-3","article-title":"The role of T follicular helper cells and T follicular regulatory cells in the pathogenesis of autoimmune hemolytic anemia","volume":"9","author":"Gao","year":"2019","journal-title":"Sci Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012924","article-title":"T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome","volume":"139","author":"Kumar","year":"2022","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01345-5","article-title":"Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota","volume":"24","author":"Liu","year":"2022","journal-title":"Nat Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00965","article-title":"Survival of long-lived plasma cells (LLPC): piecing together the puzzle","volume":"10","author":"Lightman","year":"2019","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202101285","article-title":"Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting","volume":"5","author":"Joyner","year":"2021","journal-title":"Life Sci Alliance"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.12.001","article-title":"Autoimmune hemolytic anemia: diagnosis and differential diagnosis","volume":"36","author":"Scheckel","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2216930","article-title":"Strategies to overcome the diagnostic challenges of autoimmune hemolytic anemias","volume":"16","author":"Barcellini","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23218","article-title":"The direct antiglobulin test: a critical step in the evaluation of hemolysis","volume":"87","author":"Zantek","year":"2012","journal-title":"Am J Hematol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0444-RS","article-title":"The direct antiglobulin test: indications, interpretation, and pitfalls","volume":"141","author":"Parker","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2450\/2014.0252-14","article-title":"Pitfalls in the diagnosis of autoimmune haemolytic anaemia","volume":"13","author":"Barcellini","year":"2015","journal-title":"Blood Transfus"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13888","article-title":"Paroxysmal cold hemoglobinuria: a difficult diagnosis in adult patients","volume":"57","author":"Zeller","year":"2017","journal-title":"Transfusion"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000944","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"136","author":"Luzzatto","year":"2020","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1754791","article-title":"Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures","volume":"13","author":"Barcellini","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1180509","article-title":"The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket","volume":"14","author":"Berentsen","year":"2023","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010164","article-title":"Infectious complications in autoimmune hemolytic anemia","volume":"10","author":"Giannotta","year":"2021","journal-title":"J Clin Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.04.009","article-title":"Autoimmune manifestations in patients with Waldenstr\u00f6m macroglobulinemia","volume":"14","author":"Bockorny","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.139","article-title":"Primary immunodeficiencies (PIDs) presenting with cytopenias","author":"Notarangelo","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221097780","article-title":"Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers","volume":"13","author":"Fattizzo","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00437.x","article-title":"Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study","volume":"75","author":"Kotb","year":"2005","journal-title":"Eur J Haematol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12199","article-title":"Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia","volume":"91","author":"Barcellini","year":"2013","journal-title":"Eur J Haematol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17105","article-title":"Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma","volume":"192","author":"Herishanu","year":"2021","journal-title":"Br J Haematol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"key":"B109","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1182\/blood-2024-202980","article-title":"CD19 CAR T-cell therapy in refractory autoimmune hemolytic anemia","volume":"144","author":"Li","year":"2024","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2010.12.016","article-title":"Rituximab therapy for autoimmune haematological diseases","volume":"22","author":"Barcellini","year":"2011","journal-title":"Eur J Intern Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-363556","article-title":"Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies","volume":"119","author":"Barcellini","year":"2012","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1481333","article-title":"Very low doses of rituximab in autoimmune hemolytic anemia-an open-label, phase II pilot trial","volume":"11","author":"Moser","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew267","article-title":"Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematosus","volume":"55","author":"Karageorgas","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.014","article-title":"Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results","volume":"21","author":"Pidala","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012585","article-title":"Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease","volume":"8","author":"Jalink","year":"2024","journal-title":"Blood Adv"},{"key":"B120","unstructured":"Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA) - NCI"},{"key":"B121","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1182\/blood-2024-206100","article-title":"Evaluation of obexelimab in patients with warm autoimmune hemolytic anemia: preliminary results from an open label phase 2 study","volume":"144","author":"Fattizzo","year":"2024","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01592-0","article-title":"Bruton's tyrosine kinase inhibition as an emerging therapy in systemic autoimmune disease","volume":"81","author":"Neys","year":"2021","journal-title":"Drugs"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1182\/blood-2024-200325","article-title":"Part a efficacy and safety of oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in patients with warm autoimmune hemolytic anemia (wAIHA): multicenter, open-label, phase 2b study","volume":"144","author":"Cooper","year":"2024","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.120.265538","article-title":"Parsaclisib is a next-generation phosphoinositide 3-kinase \u03b4 Inhibitor with reduced hepatotoxicity and potent antitumor and immunomodulatory activities in models of B-cell Malignancy","volume":"374","author":"Shin","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"B126","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/01.HS9.0000844036.02998.15","article-title":"S286: Long-term efficacy and safety results from an ongoing open-label phase 2 study of parsaclisib for the treatment of autoimmune hemolytic anemia (AIHA)","volume":"6","author":"Barcellini","year":"2022","journal-title":"HemaSphere"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26508","article-title":"Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study","volume":"97","author":"Kuter","year":"2022","journal-title":"Am J Hematol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ajh.27144","article-title":"Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD)","volume":"99","author":"Kuter","year":"2024","journal-title":"Am J Hematol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/S2352-3026(24)00344-2","article-title":"Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2\/3 study","volume":"12","author":"Zhao","year":"2025","journal-title":"Lancet Haematol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41598-018-19460-5","article-title":"PI3K induces B-cell development and regulates B cell identity","volume":"8","author":"Abdelrasoul","year":"2018","journal-title":"Sci Rep"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27493","article-title":"Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study","volume":"99","author":"Barcellini","year":"2024","journal-title":"Am J Hematol"},{"key":"B132","unstructured":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia\n          \n          \n          \n          2024"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk","volume":"113","author":"Podolanczuk","year":"2009","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1302714","article-title":"Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled study","volume":"18","author":"Leu","year":"2024","journal-title":"Front Neurosci"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165585","article-title":"Energy trial in warm autoimmune hemolytic anemia (wAIHA): design of a phase 2\/3 randomized, double-blind, placebo-controlled study to assess the efficacy and safety of nipocalimab, an fcRn blocker","volume":"140","author":"Murakhovskaya","year":"2022","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27487","article-title":"Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions","volume":"99","author":"Jacobs","year":"2024","journal-title":"Am J Hematol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000976904.28542.f2","article-title":"Pb2552: vayhia: A randomized, double-blind, phase iii trial to assess the efficacy and safety of ianalumab vs placebo in patients with warm autoimmune hemolytic anemia that failed \u22651 line of treatment","volume":"7","author":"Barcellini","year":"2023","journal-title":"Hemasphere"},{"key":"B138","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1182\/blood-2023-177786","article-title":"Povetacicept (ALPN-303), a potent dual BAFF\/APRIL antagonist in development for the treatment of autoimmune cytopenias, suppresses disease in a mouse model of autoimmune hemolytic anemia","volume":"142","author":"Lewis","year":"2023","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0085","article-title":"Sutimlimab for treatment of cold agglutinin disease: why, how and for whom","volume":"14","author":"Berentsen","year":"2022","journal-title":"Immunotherapy"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1111","article-title":"Randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway","volume":"104","author":"Bartko","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"B142","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/bloodadvances.2019001321","article-title":"Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program","volume":"4","author":"Gelbenegger","year":"2020","journal-title":"Blood Adv"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1182\/bloodadvances.2024013366","article-title":"Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up","volume":"8","author":"R\u00f6th","year":"2024","journal-title":"Blood Adv"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26965","article-title":"Sustained inhibition of complement C1s with sutimlimab over 2\u2009years in patients with cold agglutinin disease","volume":"98","author":"R\u00f6th","year":"2023","journal-title":"Am J Hematol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102733","article-title":"Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B","volume":"74","author":"R\u00f6th","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022153","article-title":"Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study","volume":"143","author":"D'Sa","year":"2024","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood.2023022549","article-title":"Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia","volume":"145","author":"Roman","year":"2025","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-155989","article-title":"Trial in progress: randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CASCADE)","volume":"140","author":"Jilma","year":"2022","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"key":"B153","article-title":"Efficacy of sutimlimab stratified by baseline hemoglobin in patients with cold agglutinin disease: a post hoc analysis from CARDINAL and CADENZA","volume":"8","author":"R\u00f6th","year":"2024","journal-title":"HemaSphere"},{"key":"B154","article-title":"Baseline characteristics from the first inter analysis of CADENCE, the cold agglutinin disease (CAD) \/Cold agglutinin syndrome (CAS) registry","volume":"8","author":"Michel","year":"2024","journal-title":"HemaSphere"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13481","article-title":"First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor","volume":"16","author":"Chow","year":"2023","journal-title":"Clin Transl Sci"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109629","article-title":"Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s","volume":"251","author":"Simmons","year":"2023","journal-title":"Clin Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1633883","article-title":"Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life","volume":"11","author":"Mackness","year":"2019","journal-title":"MAbs"},{"key":"B158","article-title":"Riliprubart (SAR445088) in cold agglutinin disease: interim analysis from part 2 of a long-term phase 1B trial confirms acceptable efficacy and safety with 12-weekly IV administration","volume":"8","author":"R\u00f6th","year":"2024","journal-title":"HemaSphere"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009402","article-title":"C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia","volume":"7","author":"de Boer","year":"2023","journal-title":"Blood Adv"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1056\/NEJMx240003","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Hillmen","year":"2024","journal-title":"N Engl J Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-196329","article-title":"Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease","volume":"113","author":"R\u00f6th","year":"2009","journal-title":"Blood"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1800-7","article-title":"Long-term response of refractory primary cold agglutinin disease to eculizumab therapy","volume":"93","author":"Gupta","year":"2014","journal-title":"Ann Hematol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.399","article-title":"Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity","volume":"3","author":"Shapiro","year":"2015","journal-title":"Clin Case Rep"},{"key":"B165","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"B166","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1182\/blood-2024-199637","article-title":"Iptacopan monotherapy in patients with cold agglutinin disease: phase II study results","volume":"144","author":"R\u00f6th","year":"2024","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1624667\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:08:27Z","timestamp":1753942107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1624667\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":166,"alternative-id":["10.3389\/fimmu.2025.1624667"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1624667","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"1624667"}}